Empagliflozin in carotid intima-media thickness

Not Applicable

Conditions: Condition 1: myocardial infarction. Condition 2: Type 2 diabetes.
ST elevation (STEMI) myocardial infarction of unspecified site
Type 2 diabetes mellitus without complications
I21.3
E11.9

Registration Number: IRCT20230727058945N1

Lead Sponsor: Abidi Pharmaceutical Company

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 80

Inclusion Criteria

type 2 diabetic patients with a history of glucose reducing medications
patients with STEMI with ST-segment elevation more than 0.1mv in two or more leads in ECG

Exclusion Criteria

cardiogenic shock
hypoglycemia
diabetic ketoacidosis
history of coronary artery bypass surgery
type 1 diabetes
severe liver failure
advanced cancer patients
history of allergy to Empagliflozin or ingredients
severe renal failure, ESRD, or dialysis
hypovolemia
inflammatory diseases
Cancer history
advanced heart failure
patients under 18 years of age
pregnancy

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Carotid intima-media thickness. Timepoint: Measurement of intima media thickness of carotid artery at the beginning of the study (before the intervention) and 3 months after the start of drug use. Method of measurement: B-mode and Doppler ultrasound.;Carotid resistivity index. Timepoint: Measurement of the carotid artery resistivity index at the beginning of the study (before the intervention) and 3 months after starting the drug. Method of measurement: B-mode and Doppler ultrasound.;Atherosclerotic plaques. Timepoint: Measurement of atherosclerotic plaques at the beginning of the study (before the intervention) and 3 months after starting the drug. Method of measurement: B-mode and Doppler ultrasound.

Secondary Outcome Measures